Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Kinetic Oscillation Stimulation Proves to be Therapeutically Beneficial for Chronic Migraine
March 11th 2025Treatment with the Chordate System led to a significantly greater reduction in monthly headache days during the performance assessment period, with a reduction of 3.5 days compared to 1.2 days in the sham group.
Repair, Remyelination, and Progress: What’s Driving MS Innovation in 2025?
March 11th 2025Daniel Ontaneda, MD, PhD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, gave thoughts and perspectives on some of the emerging, promising advances in multiple sclerosis care expected to come to fruition in 2025.
DMD Community Eyes First Cell Therapy Approval Following FDA’s Acceptance of Deramiocel Submission
March 4th 2025With a scheduled PDUFA date of August 31, 2025, deramiocel looks to become the first marketed treatment for cardiomyopathy in DMD, one of the leading causes of death in this patient population.
FDA Approves Expanded Use of Eculizumab for Pediatric Myasthenia Gravis
March 4th 2025Originally approved in 2007, eculizumab (Soliris; Alexion/AstraZeneca) is now available to treat both adult and pediatric patients with generalized myasthenia gravis, becoming the first available option for younger patients with the disease.
Phase 4 CLADRINA Data Supports Transition From Natalizumab to Cladribine in Multiple Sclerosis
March 3rd 2025After 24 months after switching to cladribine, 100% of patients with relapsing MS remained free from T1 gadolinium-enhancing lesions, with no reported cases of PML or rebound disease activity.
Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS
February 27th 2025The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.